This trial will study whether the drug obicetrapib is effective in treating people with a history of HeFH, a condition that causes high cholesterol. The trial will be placebo-controlled, meaning some participants will receive a placebo, and double-blind, meaning neither the participants nor the researchers will know who is receiving the drug or the placebo.
0 Primary · 10 Secondary · Reporting Duration: Percent change from baseline to Day 84, 180, and 365 in TG
Experimental Treatment
Non-Treatment Group
300 Total Participants · 2 Treatment Groups
Primary Treatment: Obicetrapib · Has Placebo Group · Phase 3
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:| Illinois | 50.0% |
| Virginia | 50.0% |
| 65+ | 100.0% |
| Overlook Medical Center | 100.0% |
| Did not meet criteria | 100.0% |
| 1 | 100.0% |